Concepedia

Author

Maureen Watt

Astellas Pharma (United Kingdom)ORCID

Also Known As

Daniel Nova Estepan, M Watt, M. Watt, Maureen Watt, Meghan M. Watt

67

Publications

601

Citations

13

H-Index

10

Concepts

All Affiliations

Astellas Pharma (United Kingdom)Takeda (United States)Fraunhofer Institute for Translational Medicine and PharmacologyCharité - Universitätsmedizin BerlinHumboldt-Universität zu Berlin
MW

About

Maureen Watt is an author at Astellas Pharma (United Kingdom) specializing in infection control, medicine, and clinical microbiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

38

2

Medicine

1

1

38

3

Antibiotics

1

1

38

4

Clinical Microbiology

1

1

38

5

Health Economics

1

1

38

Maureen Watt

×

14

Publications

495

Citations

12

H-Index

YearCitations

Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement

Maureen Watt, Stuart Mealing, James Eaton,

Heart

2011

125

Antibiotic research and development: business as usual?

Stephan Harbarth, Ursula Theuretzbacher, Judith Hackett,

Journal of Antimicrobial Chemotherapy

2015

83

A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

Maureen Watt, Charles McCrea, Sukhvinder Johal,

Infection

2016

44

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

Carlos Rubio-Terrés, Javier Cobo Reinoso, Santiago Grau Cerrato,

European Journal of Clinical Microbiology & Infectious Diseases

2015

38

The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study

Ángel Asensio, Stefano Di Bella, Andrea Lo Vecchio,

International Journal of Infectious Diseases

2015

31

Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat <i>Clostridium difficile</i> infection in France

Maureen Watt, Aurélien Dinh, Alban Le Monnier,

Journal of Medical Economics

2017

29

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness

Oliver A. Cornely, Maureen Watt, Charles McCrea,

Journal of Antimicrobial Chemotherapy

2018

29

Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study

Marcus Maurer, William R. Lumry, H. Henry Li,

The Journal of Allergy and Clinical Immunology In Practice

2023

23

Quality of life in the first 100 days after suspected acute myocardial infarction--a suitable trial endpoint?

John Rawles, Jane Light, Maureen Watt

Journal of Epidemiology & Community Health

1992

19

Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema

William R. Lumry, Marcus Maurer, Karsten Weller,

Annals of Allergy Asthma & Immunology

2023

19

Page 1